Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells.
The role of MRN in the S-phase DNA damage checkpoint is independent of its Ctp1-dependent roles in double-strand break repair and checkpoint signaling.
Trends in COVID-19 vaccine administration across visit types in a safety net pediatric practice during the first year of authorization.
Grid-enabled measures: using Science 2.0 to standardize measures and share data.
Has thrombolytic therapy changed the equation for postinfarction risk stratification?
See All 7 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Has thrombolytic therapy changed the equation for postinfarction risk stratification?
Aurigemma G. Has thrombolytic therapy changed the equation for postinfarction risk stratification? Lancet. 1997 Feb 01; 349(9048):298-9.
View in:
PubMed
subject areas
Diagnostic Imaging
Echocardiography
Exercise Test
Humans
Myocardial Infarction
Patient Discharge
Prognosis
Risk Assessment
Thrombolytic Therapy
authors with profiles
Gerard P Aurigemma MD